iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Stock Information for iBio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About iBio Inc.

iBio to Participate in the 8th Annual Evercore Healthcare Conference
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
iBio Announces Closing of $50 Million Public Offering
iBio Announces Pricing of $50 Million Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.